Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00614354 · ClinicalTrials.gov registry record · Phase 2
Study of 99mTc-glucarate to Detect Acute Coronary Syndrome in Chest Pain Patients.
A Phase 2 study, sponsored by Molecular Targeting Technologies.
- Completed
- Registry status
- Phase 2
- Development phase
- 66
- Enrollment target
NCT00614354: Completed Phase 2 study, sponsored by Molecular Targeting Technologies.
NCT00614354 is a Phase 2 study that has completed, run by Molecular Targeting Technologies. The registered enrollment target is 66 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (50% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00614354, a Phase 2 study, has completed, sponsored by Molecular Targeting Technologies.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 66 participants
- Enrollment target
Study Summary
The purpose of this clinical trial is to study the ability of a radioactive drug called "Technetium Glucarate" to detect whether the cause of chest pain in patients entering the emergency department with no obvious signs of heart attack is due to a condition called Acute Coronary Syndrome (ACS). The drug will be injected intravenously. After one or two hours the patient will undergo an imaging procedure to detect if the drug has accumulated in the heart. Uptake of the radioactive drug in the heart is indicative of reduced blood flow to the heart.
Interventions
- DRUG 99mTc-glucarate solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2008-10 |
| Est. Completion | 2010-09 |
| Phase | Phase 2 |
What the finished NCT00614354 record still lists
NCT00614354 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 66 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (50% lower).
The record links to 0 conditions, and to 1 intervention - of which 99mTc-glucarate solution is the first listed.
NCT00614354 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00614354 about?
NCT00614354 is a clinical study titled "Study of 99mTc-glucarate to Detect Acute Coronary Syndrome in Chest Pain Patients.". The purpose of this clinical trial is to study the ability of a radioactive drug called "Technetium Glucarate" to detect whether the cause of chest pain in patients entering the emergency department with no obvious signs of heart attack is due to a condition called Acute Coronary Syndrome (ACS). The...
What is the current status of trial NCT00614354?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 66 participants. The study started on 2008-10. Estimated completion is 2010-09.
What interventions are being tested in trial NCT00614354?
The interventions under investigation include: 99mTc-glucarate solution (DRUG).
Who is sponsoring clinical trial NCT00614354?
This trial is sponsored by Molecular Targeting Technologies, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00614354's enrollment target sits among peer trials
66 975th of 2000 higher than 1,014 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02584244 · 66 participants · Phase 1
Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers
- NCT03067051 · 66 participants · Phase 1
Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System
- NCT03754725 · 66 participants · Phase 1
Ferritin and Iron Burden in SAH sIRB
- NCT03875378 · 66 participants · Phase 2
Transdermal Estrogen in Women With Anorexia Nervosa
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia